Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288719467> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W4288719467 endingPage "164" @default.
- W4288719467 startingPage "164" @default.
- W4288719467 abstract "Background: Lung cancer has the highest mortality rates and one of the lowest 5-year survival rates amongst cancer types in the world. Although there are constant advancements in treatment, the overall prognosis for lung cancer continues to be poor. In order to achieve early detection and personalized targeted treatment, an effective method is needed to make prognostic and treatment decisions. Methods: A thorough literature search was conducted to identify tumor tissue, blood, and expired breath markers that have been discovered in lung cancer. Articles were chosen by determining main markers holding promise for future clinical use. Results: Data suggests significance in using tumor tissue markers as promising diagnostic, prognostic and predictive of treatment response and outcome. Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) and ROS-1 biomarkers can be used to decide to treat with EGFR-TKI and ALK-TKI, respectively. KRAS and p53 mutations suggest a likelihood of developing EGFR-TKI resistance. And c-MET is showing pertinence in predicting disease recurrence. Blood and expired breath markers are two more novel sources for biomarkers that is gaining more ground in lung cancer research. Circulating tumor cells (CTC) and DNA (ctDNA) were shown to be important markers in lung cancer prognosis and treatment response prediction. Circulating tumor cells suggest negative prognosis and increased likelihood of recurrence, while ctDNA data indicates use in treatment monitoring to help make decisions without keeping patients on disagreeable therapies. Volatile organic compounds (VOC) are the least studied, but investigators have noticed changes in VOC profiles between healthy and lung cancer patients. Blood and expired breath markers continue to be studied as these would be a welcome alternative to invasive biopsies. Recently there had been interest in using specific tumor biomarkers for imaging to localize tumors and determine disease progression. Conclusions: Years of research have elucidated multiple candidates as biomarkers found in tumor tissues, circulation, and even in exhaled air. Although more studies need to be performed on some markers mentioned in this review, such as EGFR, KRAS, ALK, and ROS-1, there is enough evidence for some use of these biomarkers to guide decisions in clinic, as well as evidence for promising future developments." @default.
- W4288719467 created "2022-07-30" @default.
- W4288719467 creator A5020214405 @default.
- W4288719467 creator A5023577703 @default.
- W4288719467 date "2022-07-28" @default.
- W4288719467 modified "2023-09-28" @default.
- W4288719467 title "Molecular Markers in Guiding Lung Cancer Diagnosis and Treatment" @default.
- W4288719467 doi "https://doi.org/10.31083/j.jomh1808164" @default.
- W4288719467 hasPublicationYear "2022" @default.
- W4288719467 type Work @default.
- W4288719467 citedByCount "1" @default.
- W4288719467 countsByYear W42887194672023 @default.
- W4288719467 crossrefType "journal-article" @default.
- W4288719467 hasAuthorship W4288719467A5020214405 @default.
- W4288719467 hasAuthorship W4288719467A5023577703 @default.
- W4288719467 hasBestOaLocation W42887194671 @default.
- W4288719467 hasConcept C117643217 @default.
- W4288719467 hasConcept C121608353 @default.
- W4288719467 hasConcept C126322002 @default.
- W4288719467 hasConcept C143998085 @default.
- W4288719467 hasConcept C2776232967 @default.
- W4288719467 hasConcept C2776256026 @default.
- W4288719467 hasConcept C2779013556 @default.
- W4288719467 hasConcept C2779438470 @default.
- W4288719467 hasConcept C2780521871 @default.
- W4288719467 hasConcept C2781187634 @default.
- W4288719467 hasConcept C526805850 @default.
- W4288719467 hasConcept C61238886 @default.
- W4288719467 hasConcept C71924100 @default.
- W4288719467 hasConceptScore W4288719467C117643217 @default.
- W4288719467 hasConceptScore W4288719467C121608353 @default.
- W4288719467 hasConceptScore W4288719467C126322002 @default.
- W4288719467 hasConceptScore W4288719467C143998085 @default.
- W4288719467 hasConceptScore W4288719467C2776232967 @default.
- W4288719467 hasConceptScore W4288719467C2776256026 @default.
- W4288719467 hasConceptScore W4288719467C2779013556 @default.
- W4288719467 hasConceptScore W4288719467C2779438470 @default.
- W4288719467 hasConceptScore W4288719467C2780521871 @default.
- W4288719467 hasConceptScore W4288719467C2781187634 @default.
- W4288719467 hasConceptScore W4288719467C526805850 @default.
- W4288719467 hasConceptScore W4288719467C61238886 @default.
- W4288719467 hasConceptScore W4288719467C71924100 @default.
- W4288719467 hasIssue "8" @default.
- W4288719467 hasLocation W42887194671 @default.
- W4288719467 hasOpenAccess W4288719467 @default.
- W4288719467 hasPrimaryLocation W42887194671 @default.
- W4288719467 hasRelatedWork W1591408781 @default.
- W4288719467 hasRelatedWork W1889913689 @default.
- W4288719467 hasRelatedWork W2134370756 @default.
- W4288719467 hasRelatedWork W2374494252 @default.
- W4288719467 hasRelatedWork W2589642515 @default.
- W4288719467 hasRelatedWork W2611871978 @default.
- W4288719467 hasRelatedWork W2980544234 @default.
- W4288719467 hasRelatedWork W2998686349 @default.
- W4288719467 hasRelatedWork W3029378535 @default.
- W4288719467 hasRelatedWork W4288752844 @default.
- W4288719467 hasVolume "18" @default.
- W4288719467 isParatext "false" @default.
- W4288719467 isRetracted "false" @default.
- W4288719467 workType "article" @default.